Why the study?
Does orally administered rhesus rotavirus vaccine prevent rotavirus-associated illnesses in infants aged 2 to 4 months?
Population
176 infants (ages 2 to 4 months)
Comparison
Orally administered rhesus rotavirus vaccine… vs Placebo
Design
RCT, placebo-controlled
Authors
Loading...
Rhesus rotavirus vaccine should not be used in infants; challenges reliance on neutralizing antibody rise as a surrogate for clinical protection.
Does orally administered rhesus rotavirus vaccine prevent rotavirus-associated illnesses in infants aged 2 to 4 months?
Orally administered rhesus rotavirus vaccine (serotype 3) was immunogenic but failed to protect against rotavirus-associated illnesses, likely due to a mismatch with circulating serotype 1 strains.
Christy et al. (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: